Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma

J. Skoda, M. Hermanova, T. Loja, P. Nemec, J. Neradil, P. Karasek, R. Veselska,

. 2016 ; 11 (7) : e0159255. [pub] 20160714

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17031587

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Its dismal prognosis is often attributed to the presence of cancer stem cells (CSCs) that have been identified in PDAC using various markers. However, the co-expression of all of these markers has not yet been evaluated. Furthermore, studies that compare the expression levels of CSC markers in PDAC tumor samples and in cell lines derived directly from those tumors are lacking. Here, we analyzed the expression of putative CSC markers-CD24, CD44, epithelial cell adhesion molecule (EpCAM), CD133, and nestin-by immunofluorescence, flow cytometry and quantitative PCR in 3 PDAC-derived cell lines and by immunohistochemistry in 3 corresponding tumor samples. We showed high expression of the examined CSC markers among all of the cell lines and tumor samples, with the exception of CD24 and CD44, which were enriched under in vitro conditions compared with tumor tissues. The proportions of cells positive for the remaining markers were comparable to those detected in the corresponding tumors. Co-expression analysis using flow cytometry revealed that CD24+/CD44+/EpCAM+/CD133+ cells represented a significant population of the cells (range, 43 to 72%) among the cell lines. The highest proportion of CD24+/CD44+/EpCAM+/CD133+ cells was detected in the cell line derived from the tumor of a patient with the shortest survival. Using gene expression profiling, we further identified the specific pro-tumorigenic expression profile of this cell line compared with the profiles of the other two cell lines. Together, CD24+/CD44+/EpCAM+/CD133+ cells are present in PDAC cell lines derived from primary tumors, and their increased proportion corresponds with a pro-tumorigenic gene expression profile.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031587
003      
CZ-PrNML
005      
20171025123047.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0159255 $2 doi
035    __
$a (PubMed)27414409
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Skoda, Jan $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
245    10
$a Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma / $c J. Skoda, M. Hermanova, T. Loja, P. Nemec, J. Neradil, P. Karasek, R. Veselska,
520    9_
$a Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Its dismal prognosis is often attributed to the presence of cancer stem cells (CSCs) that have been identified in PDAC using various markers. However, the co-expression of all of these markers has not yet been evaluated. Furthermore, studies that compare the expression levels of CSC markers in PDAC tumor samples and in cell lines derived directly from those tumors are lacking. Here, we analyzed the expression of putative CSC markers-CD24, CD44, epithelial cell adhesion molecule (EpCAM), CD133, and nestin-by immunofluorescence, flow cytometry and quantitative PCR in 3 PDAC-derived cell lines and by immunohistochemistry in 3 corresponding tumor samples. We showed high expression of the examined CSC markers among all of the cell lines and tumor samples, with the exception of CD24 and CD44, which were enriched under in vitro conditions compared with tumor tissues. The proportions of cells positive for the remaining markers were comparable to those detected in the corresponding tumors. Co-expression analysis using flow cytometry revealed that CD24+/CD44+/EpCAM+/CD133+ cells represented a significant population of the cells (range, 43 to 72%) among the cell lines. The highest proportion of CD24+/CD44+/EpCAM+/CD133+ cells was detected in the cell line derived from the tumor of a patient with the shortest survival. Using gene expression profiling, we further identified the specific pro-tumorigenic expression profile of this cell line compared with the profiles of the other two cell lines. Together, CD24+/CD44+/EpCAM+/CD133+ cells are present in PDAC cell lines derived from primary tumors, and their increased proportion corresponds with a pro-tumorigenic gene expression profile.
650    _2
$a antigen AC133 $x metabolismus $7 D000071916
650    _2
$a adenokarcinom $x diagnóza $x metabolismus $7 D000230
650    _2
$a senioři $7 D000368
650    _2
$a antigen CD24 $x metabolismus $7 D051927
650    _2
$a antigeny CD44 $x metabolismus $7 D018960
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a kultivované buňky $7 D002478
650    _2
$a adhezní molekula epiteliálních buněk $x metabolismus $7 D000071858
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nestin $x metabolismus $7 D064231
650    _2
$a nádory slinivky břišní $x diagnóza $x metabolismus $7 D010190
650    _2
$a prognóza $7 D011379
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a kmenové buňky $x metabolismus $7 D013234
650    _2
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hermanova, Marketa $u 1st Department of Pathological Anatomy, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Loja, Tomas $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Nemec, Pavel $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Neradil, Jakub $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Karasek, Petr $u Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Veselska, Renata $u Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 7 (2016), s. e0159255
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27414409 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025123129 $b ABA008
999    __
$a ok $b bmc $g 1255180 $s 992614
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 7 $d e0159255 $e 20160714 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20171025
Back

Find record

Citation metrics

Archiving options